These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16895843)

  • 1. Manufacture, characterization, and pharmacodynamic evaluation of engineered ipratropium bromide particles.
    Taylor MK; Hickey AJ; VanOort M
    Pharm Dev Technol; 2006; 11(3):321-36. PubMed ID: 16895843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3415-29. PubMed ID: 20222025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies.
    Kaye RS; Purewal TS; Alpar HO
    J Pharm Sci; 2009 Nov; 98(11):4055-68. PubMed ID: 19189420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalable Ipratropium Bromide Particle Engineering with Multicriteria Optimization.
    Vinjamuri BP; Haware RV; Stagner WC
    AAPS PharmSciTech; 2017 Aug; 18(6):1925-1935. PubMed ID: 27873181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations.
    Shur J; Kubavat HA; Ruecroft G; Hipkiss D; Price R
    J Pharm Pharmacol; 2012 Sep; 64(9):1326-36. PubMed ID: 22881444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ipratropium bromide on pulmonary hemodynamics in COPD.
    Zieliński J
    Chest; 1995 Oct; 108(4):1181-2. PubMed ID: 7555146
    [No Abstract]   [Full Text] [Related]  

  • 10. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
    Razavi Rohani SS; Abnous K; Tafaghodi M
    Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
    Cazzola M; Santus P; D'Adda A; Pizzolato S; Di Marco F; Centanni S
    Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.
    Tashkin DP
    Expert Opin Drug Saf; 2015; 14(11):1759-72. PubMed ID: 26401729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
    Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
    Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
    Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
    Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics.
    Coowanitwong I; Arya V; Patel G; Kim WS; Craciun V; Rocca JR; Singh R; Hochhaus G
    J Pharm Pharmacol; 2007 Nov; 59(11):1473-84. PubMed ID: 17976257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhalation of high-doses of ipratropium bromide (Atrovent) does not cause any changes in systemic or pulmonary hemodynamics].
    Král B; Gregor J; Parízek P; Pudil R; Jílková V
    Cas Lek Cesk; 2000 Feb; 139(2):49-50. PubMed ID: 10802931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhalable DNase I microparticles engineered with biologically active excipients.
    Osman R; Al Jamal KT; Kan PL; Awad G; Mortada N; El-Shamy AE; Alpar O
    Pulm Pharmacol Ther; 2013 Dec; 26(6):700-9. PubMed ID: 23933140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J; Chan HK; Gengenbach T; Denman JA
    Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
    Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
    Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary targeting of sustained release formulation of budesonide in neonatal rats.
    Arya V; Coowanitwong I; Brugos B; Kim WS; Singh R; Hochhaus G
    J Drug Target; 2006 Dec; 14(10):680-6. PubMed ID: 17162737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.